Scientific Journals

	Original Artikel	Journal	Datum	Titel	Autoren Alle Autoren
1	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2025―Okt―28	Risks of drug interactions of antibacterial drugs used in the treatment of nosocomial pneumonia associated with coronavirus infection	Ya. G. Amelina, O. M. Romashov, N. V. Teplova, O. S. Gerasimova
2	[GO]	Antibiotics and Chemotherapy	2025―Jun―09	Evaluation of the Effectiveness of Riamilovir in Prevention of COVID-19: Mathematical Simulation Results	A. S. Sigidaev, P. B. Zotov, V. A. Duldin, I. I. Iva, K. V. Kozlov, O. V. Maltsev, et al. (+2) V. V. Ivanova, K. Bryanskaya-Kasyanenko
3	[GO]	Antibiotics and Chemotherapy	2025―Jun―09	On the Safety of COVID-19 Vaccine Prophylaxis in Rheumato- logical Patients: Results and Prospects	B. S. Belov, N. V. Muravyeva, O. B. Perepechaeva
4	[GO]	Antibiotics and Chemotherapy	2025―Jun―09	Current Perspective on the Treatment of the Novel Coronavirus Infection COVID-19	I. Kh. Borukaeva, Z. Kh. Abazova, Z. A. Kambachokova, A. A. Kambachokova, A. A. Kardanov, M. S. Djabrailova, et al. (+6) Z. I. Сhanieva, Kh. Kh. Akhmatov, M. A. Abdurakhmanov, Sh. M. Baskariev, E. B. Mezhikhova, D. A. Shogenova
5	[GO]	Antibiotics and Chemotherapy	2025―Apr―20	The Susceptibility of Klebsiella Pneumoniae Strains Isolated from COVID-19 Patients to Commercially Available Bacteriophage Medications	B. I. Aslanov, A. E. Goncharov, S. D. Konev, A. S. Mochov, D. A. Azarov, E. А. Lebedeva, et al. (+6) A. V. Kuleshova, V. V. Kolodzhieva, E. N. Kolosovskaya, A. M. Nifontova, D, A. Lioznov
6	[GO]	Antibiotics and Chemotherapy	2025―Apr―20	Antiviral Activity of 5-chloropyridin-3-yl-1h-indole-4-carboxylate (AMND) Against COVID-19	S. Ya. Loginova, V. N. Shсhukina, S. V. Savenko, V. V. Rubtsov, D. A. Kutayev, S. V. Borisevich, et al. (+6) V. A. Kovtun, N. I. Mosin, M. M. Muradov, V. L. Volkov, A. S. Belyaev, A. B. Predtechensky
7	[GO]	Patient-Oriented Medicine and Pharmacy	2025―Mrz―26	Clinical indices and laboratory markers for evaluating the immune-mediated inflammation in rheumatoid arthritis: the impact of COVID-19	K. M. Konovalov, A. A. Baranov, N. A. Lapkina, N. E. Abaytova, O. L. Borisova
8	[GO]	Patient-Oriented Medicine and Pharmacy	2025―Mrz―07	Physical and health development of female medical university students studying remotely during the COVID-19 pandemic	M. A. Gansburgsky
9	[GO]	Antibiotics and Chemotherapy	2025―Feb―10	Analysis of the Distribution Pattern of Genetic Biomarkers of Safety of Etiotropic Drugs for the Treatment of COVID-19 in Representatives of Ethnic Groups of the Volga Region and the Far East	S. N. Tuchkova, Sh. P. Abdullaev, N. P. Denisenko, A. V. Kryukov, I. I. Temirbulatov, S. S. Suleymanov, et al. (+6) E. Y. Kitaeva, V. V. Shprakh, E. E. Sidukova, I. V. Sychev, K. B. Mirzaev, D. A. Sychev
10	[GO]	Antibiotics and Chemotherapy	2024―Nov―22	Temporal Dynamics of the Resistome of the Intestinal Microbiota of a Healthy Population against the Background of COVID-19	A. V. Pavlenko, A. I. Manolov, Yu. I. Esin, A. L. Arkhipova, A. V. Vvedenskiy, A. V. Kudryavtsev, et al. (+5) E. A. Krieger, L. L. Shagrov, N. I. Belova, E. N, Ilyina
11	[GO]	Antibiotics and Chemotherapy	2024―Nov―22	Dynamics of Matrix Metalloproteinase-9 Levels in the Novel Coronavirus Infection COVID-19	A. U. Sabitov, Yu. B. Khamanova, Yu. N. Moskaleva, E. Yu. Kamaev, P. L. Kuznetsov, M. D. Medvedeva
12	[GO]	Antibiotics and Chemotherapy	2024―Jun―21	Comparative Analysis of the Antiviral Activity of Various Drugs Based on 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide (Favipiravir) Against COVID-19	S. Ya. Loginova, V. N. Schukina, S. V. Savenko, V. V. Rubtsov, S. V. Borisevich, D. L. Chizhov, et al. (+5) G. L. Rusinov, E. V. Verbitskiy, V. N. Charushin, S. K. Kotovskaya, V. L. Rusinov
13	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2024―Apr―21	Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19	S. K. Zyryanov, O. I. Butranova, A. A. Abramova
14	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2024―Apr―21	Opportunities for using telemedicine based on the COVID-19 pandemic	F. T. Malykhin
15	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2024―Apr―21	Adverse drug events among hospitalized COVID-19 patients. Experience with the Global Trigger Tool	S. A. Mishinova, A. S. Kolbin, E. V. Verbitskaya, N. P. Alekseeva, Yu. M. Gomon
16	[GO]	Antibiotics and Chemotherapy	2024―Apr―16	Epidemic situation and features of accompanying therapy in the treatment of socially significant infectious diseases in penitentiary populations before, during, and after the COVID-19 pandemic	V. M. Kolomiets, N. A. Polshikova, A. Yu. Petrov, A. L. Kovalenko, E. V. Talikova
17	[GO]	Antibiotics and Chemotherapy	2024―Apr―16	Efficacy and safety of oral antiviral therapy medications in the treatment of moderate and severe cases of COVID-19. Results of a comparative retrospective observational study	A. U. Sabitov, E. P. Tikhonova, E. V. Esaulenko, P. L. Kuznetsov, A. A. Sharova, T. A. Yelistratova, et al. (+5) Yu. S. Kalinina, I. V. Andreeva, V. V. Basina, E. V. Oleinichenko, A. S. Edin
18	[GO]	Antibiotics and Chemotherapy	2024―Jan―16	Cardiotoxic Drugs Used in the Treatment of COVID-19	A. S. Zmitrukevich, A. E. Mamedova
19	[GO]	Antibiotics and Chemotherapy	2024―Jan―16	Present Strategy and Tactics of Antibacterial Therapy for Hospital Infections: Lessons Learned from the COVID-19 Pandemic	S. D. Mitrokhin, A. V. Aleshkin, A. A. Galitskiy, A. S. Shkoda
20	[GO]	Antibiotics and Chemotherapy	2023―Dez―27	Distribution of Genetic Factors Associated with Severe COVID-19 in Ethnic Groups of the Eastern Caucasus	S. Р. Abdullaev, К. М.-В. Mammaev, N. Р. Denisenko, I. L. Temirbulatov, A. А. Kachanova, E. V. Mikhaylenko, et al. (+5) А. V. Kryukov, Т. Т. Valiev, К. В. Mirzaev, S. N. Mammaev, D. А. Sychev
21	[GO]	Antibiotics and Chemotherapy	2023―Dez―27	Relief from Toxic Effects of Oxygen Using Succinates in Patients with COVID-19 Undergoing High-Flow Oxygen Therapy	N. V. Govorova, S. V. Tsilina, I. A. Khilenko, V. V. Rezvykh, Yu. Р. Orlov
22	[GO]	Antibiotics and Chemotherapy	2023―Okt―23	Non-Specific Means of Medical Protection Against COVID-19	T. E. Sizikova, E. V. Lebedinskaya, O. V. Chukhralya, A. A. Petrov, V. N. Lebedev, S. V. Borisevich
23	[GO]	Antibiotics and Chemotherapy	2023―Okt―23	Dynamics of Reserve Antimicrobial Drug Consumption in Russian Hospitals: Impact of the COVID-19 Pandemic	Y. M. Gomon, A. A. Kolbin, D. S. Budanov
24	[GO]	Antibiotics and Chemotherapy	2023―Okt―23	Pharmacogenetic Markers of Favipiravir Safety in COVID-19 Treatment	I. I. Temirbulatov, A. V. Kryukov, K. B. Mirzaev, N. P. Denisenko, S. P. Abdullaev, A. V. Petrova, et al. (+3) E. P. Tkach, A. V. Shipacheva, D. A. Sychev
25	[GO]	Antibiotics and Chemotherapy	2023―Jul―18	A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy	Yu. M. Gomon, A. S. Kolbin, A. M. Fahrutdinova, T. A. Usmanova, F. M. Sultanova, Yu. E. Balykina
26	[GO]	Antibiotics and Chemotherapy	2023―Jul―18	Clinical and Laboratory Characteristics of Patients with COVID-19 on the Background of Cardiovascular Diseases	Z. A. Kambachokova, Z. A. Akhkubekova, R. M. Aramisova, D. E. Altudova, L. A. Kagazheva, M. A. Shokueva, et al. (+5) A. A. Kambachokova, A. B. Kankulova, A. M. Urusbiev, Yusufzai Abdul Vadzhid, I. A. Kochesokova
27	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2023―Apr―19	Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19	S. A. Mishinova, Yu. M. Gomon, A. S. Kolbin, E. V. Verbitskaya, T. I. Galimov
28	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2023―Mrz―02	Specifics of motivation of volunteers participating in in a clinical trial of the COVID-19 vaccine	Y. D. Belousova, V. V. Rafalsky, E. D. Kislova
29	[GO]	Antibiotics and Chemotherapy	2023―Feb―11	Is There a Need to Widely Prescribe Antibiotics in Patients with COVID-19?	N. A. Karoli, A. P. Rebrov
30	[GO]	Antibiotics and Chemotherapy	2022―Dez―29	Antiviral Activity of The Preparation Meflokhin® Against COVID-19	S. Ya. Loginova, V. N. Shhukina, S. V. Savenko, S. V. Borisevich, K. N. Filin, I. A. Berzin, V. D. Gladkikh
31	[GO]	Antibiotics and Chemotherapy	2022―Dez―29	Antimicrobial Therapy and COVID-19 - the 'Great Confrontation'	A. A. Zaytsev, A. М. Makarevich
32	[GO]	Antibiotics and Chemotherapy	2022―Nov―29	Antiviral Activity of Interferon alfa-2b and Taurine Combination Against SARS-CoV-2 <i>in vitro</i>	N. P. Kartashova, A. V. Ivanina, E. A. Glubokova, I. N. Falynskova, A. A. Poromov, I. A. Leneva
33	[GO]	Antibiotics and Chemotherapy	2022―Nov―18	The Effect of Carriage of <i>CYP3A53</i> and <i>CYP3A422</i> Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19	I. I. TEMIRBULATOV, A. V. KRYUKOV, K. B. MIRZAEV, N. P. DENISENKO, S. P. ABDULLAEV, A. S. ZHIRYAKOVA, et al. (+4) Y. V. SHEVCHUK, V. I. VECHORKO, O. V. AVERKOV, D. A. SYCHEV
34	[GO]	Antibiotics and Chemotherapy	2022―Nov―18	The Problem of Comorbid Socially Significant Infections Under The Conditions of The COVID-19 Pandemic	V. M. KOLOMIETS, N. A. POLSHIKOVA, A. L. KOVALENKO, E. P. PAVLENKO
35	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2022―Nov―15	The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective	A. L. Khokhlov, J. V. Rybachkova
36	[GO]	Antibiotics and Chemotherapy	2022―Sep―10	Cycloferon as a Means for Prevention, Treatment, and Control of COVID-19: Multidisciplinary and Comparative Historical Aspects	P. V. MAZIN, R. K. KHAFISIANOVA, V. P. MAZIN, A. A. GALKIN, A. K. OSKANOV
37	[GO]	Antibiotics and Chemotherapy	2022―Sep―10	Immunogenicity of Vaccines Against SARS-CoV-2 In Patients With Rheumatic Diseases	B. B. BELOV, N. V. MURAVYEVA, A. N. KULIKOV
38	[GO]	Antibiotics and Chemotherapy	2022―Aug―07	Medical Rehabilitation of Elderly and Senior Patients with COVID-19-Associated Pneumonia	M. I. Ivanova, V. M. Ivanov, Yu. M. Shcheglova, A. L. Kovalenko, E. V. Talikova
39	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2022―Mai―02	Lifestyle Changes in Medical Students during the COVID-19 Pandemic	V. A. Sergeeva, T. E. Lipatova
40	[GO]	Antibiotics and Chemotherapy	2022―Apr―16	Neuroprotective Therapy for Neurological Complications of the Novel Coronavirus Infection COVID-19	Ju. L. Lukyanova, S. A. Lukyanov, K. G. Shapovalov
41	[GO]	Antibiotics and Chemotherapy	2022―Apr―16	Antibacterial Therapy of Patients With COVID-19 During The Outpatient and Hospital Stages	N. A. Karoli, A. V. Aparkina, E. V. Grigoryeva, N. A. Magdeeva, N. M. Nikitina, N. D. Smirnova, A. P. Rebrov
42	[GO]	Real-World Data & Evidence	2022―Mrz―29	Aspects of the safe use of medicinal products based on medicinal plant materials in COVID-19	A. A. Taube
43	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2022―Feb―14	Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg	A. A. Kurylev, A. A. Zhuravkov, A. S. Kolbin
44	[GO]	Pharmacogenetics and Pharmacogenomics	2022―Jan―11	Pharmacogenetics of antiviral agents for the treatment of COVID-19	I. I. Temirbulatov, A. V. Kryukov, D. A. Sychev
45	[GO]	Real-World Data & Evidence	2021―Dez―06	Paracetamol safety in COVID-19	B. K. Romanov
46	[GO]	Antibiotics and Chemotherapy	2021―Okt―21	Seaweed-Derived Sulfated Polysaccharides as Potential Agents for Prevention and Treatment of Inﬂuenza and COVID-19	N. N. Besednova, T. N. Zvyagintseva, B. G. Andriukov, T. S. Zaporozhets, T. A. Kuznetsova, S. P. Kryzhanovsky, et al. (+2) L. G. Guseva, M. Yu. Shchelkanov
47	[GO]	Antibiotics and Chemotherapy	2021―Okt―21	Problem of Drug Interactions in the Treatment of Patients with COVID-19 and Comorbid Conditions	R. M. Aramisova, Z. A. Kambachokova, Z. A. Akhkubekova, L. L. Logvina, M. M. Sarbasheva, S. M. Chudopal, et al. (+4) L. B. Tlapshokova, L. M. Taukenova, A. R. Tambiev, K. R. Pshukov
48	[GO]	Antibiotics and Chemotherapy	2021―Okt―21	COVID-19 Therapy: the Role of Antirheumatic Drugs	M. A. Litvinova, N. V. Muravyeva, B. S. Belov
49	[GO]	Antibiotics and Chemotherapy	2021―Okt―21	Study of Riamilovir Activity Against SARS-CoV-2 Infection In Syrian Hamsters	S. V. Chepur, A. V. Smirnova, A. N. Kirienko, I. A. Myasnikova, B. A. Kanevsky, P. V. Sorokin
50	[GO]	Antibiotics and Chemotherapy	2021―Aug―30	Possibilities of suppressing the cytopathogenic effect of SARS-CoV-2 coronavirus according to the results of the antiviral activity of Cytovir®-3 in vitro study	V. S. Smirnov, I. A. Leneva, T. A. Kudryavtseva, E. B. Fayzuloev, V. A. Zaplutanov, S. V. Petlenko, et al. (+3) N. P. Kartashova, A. V. Gracheva, E. R. Korchevaya
51	[GO]	Antibiotics and Chemotherapy	2021―Aug―30	Local antiviral activity of the drug «Thymogen®», nasal dosed spray, against SARS-CoV-2 coronavirus in vitro	I. A. Leneva, V. S. Smirnov, T. A. Kudryavtseva, E. B. Fayzuloev, A. V. Gracheva, N. P. Kartashova, et al. (+2) V. A. Zaplutanov, S. V. Petlenko
52	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2021―Aug―13	COVID-19: economic aspects of inﬂuenza vaccine prevention	E. A. Zhidkova, E. M. Gutor, Yu. A. Tkachenko, I. V. Rogova, I. A. Popova, K. G. Gurevich
53	[GO]	Antibiotics and Chemotherapy	2021―Jun―25	Possibilities of Hyperinflammation Correction in COVID-19	I. S. Simutis, G. A. Boyarinov, M. Yu. Yuriev, D. S. Petrovsky, A. L. Kovalenko, S. A. Parfenov
54	[GO]	Antibiotics and Chemotherapy	2021―Jun―25	Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach	K. A. Zykov, E. A. Sinitsyn, A. V. Rvacheva, A. O. Bogatyreva, A. A. Zykova, T. V. Shapovalenko
55	[GO]	Antibiotics and Chemotherapy	2021―Jun―25	Polyphenols Sourced from Terrestrial and Marine Plants as Coronavirus Reproduction Inhibitors	N. N. Besednova, B. G. Andryukov, T. S. Zaporozhets, T. A. Kuznetsova, S. P. Kryzhanovskiy, L. N. Fedyanina, et al. (+3) I. D. Makarenkova, I. V. Galkina, M. Yu. Shchelkanov
56	[GO]	Pharmacokinetics and Pharmacodynamics	2021―Jun―23	Combined oral contraception and treatment of new coronavirus infection (COVID-19): drug interaction issues	O. A. Limanova, O. A. Gromova, L. E. Fedotova
57	[GO]	Antibiotics and Chemotherapy	2021―Mai―07	The Eﬃcacy and Safety of Riamilovir in the Treatment of Patients with COVID-19	А. U. Sabitov, Р. V. Sorokin, S. U. Dashutina
58	[GO]	Antibiotics and Chemotherapy	2021―Mai―07	The Prospects of Succinates’ Use under Hypoxic Conditions in COVID-19	Yu. Р. Orlov, V. V. Afanasyev, I. A. Khilenko
59	[GO]	Antibiotics and Chemotherapy	2021―Mai―07	Baricitinib in the Treatment of Patients with COVID-19: A Review of International Data and Analysis of Clinical Results in the Russian Population	А. I. Zagrebneva, Е. А. Baryakh, Е. I. Zhelnova, N. G. Poteshkina, I. Р. Beloglazova, Z. Yu. Mutovina, et al. (+8) I. V. Samsonova, Е. А. Kovalevskaya, V. V. Parshin, V. V. Pshenichnikova, D S. Fomina, Т. S. Kruglova, М. А. Lysenko, М. А. Dranitsyna
60	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2021―Mrz―12	Socioeconomic and global burden of COVID-19	A. S. Kolbin, Yu. M. Gomon, Yu. E. Balykina, D. Yu. Belousov, V. V. Strizheletskiy, I. G. Ivanov
61	[GO]	Antibiotics and Chemotherapy	2021―Feb―15	Cytokine Storm in the Novel Coronavirus Infection and Methods of its Correction	A. V. Ershov, V. D. Surova, V. T. Dolgikh, T. I. Dolgikh
62	[GO]	Antibiotics and Chemotherapy	2021―Feb―15	Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection	K. V. Kasyanenko, O. V. Maltsev, K. V. Kozlov, I. I. Lapikov, N. I. Lvov, V. S. Sukachev, et al. (+3) K. V. Zhdanov, P. V. Sorokin, A. K. Ratnikova
63	[GO]	Antibiotics and Chemotherapy	2020―Nov―23	Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19	A. U. Sabitov, V. V. Belousov, A. S. Edin, E. V. Oleinichenko, E. P. Gladunova, E. P. Tikhonova, et al. (+3) T. Yu. Kuzmina, Yu. S. Kalinina, P. V. Sorokin
64	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19	V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
65	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Current and future use of angiotensin II receptor blockers in patients with COVID-19	A. V. Matveev, V. A. Otdelenov, D. A. Sychev
66	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Possibilities for the use of tofacitinib in patients with COVID-19	A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev
67	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19	V. A. Otdelenov, Yu. Yu. Kiselev, K. B. Mirzaev, A. V. Matveev, D. A. Sychev
68	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Possibilities for the use of anakinra in COVID-19	V. A. Otdelenov, A. V. Matveev, D. A. Sychev
69	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Rationality of routine clinical use of olokizumab in COVID-19	V. M. Tsvetov, A. V. Matveev, D. A. Sychev
70	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Current and future use of colchicine in patients with COVID-19	Yu. Yu. Kiselev, A. V. Matveev, D. A. Sychev
71	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Current and future use of umifenovir in patients with COVID-19	Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, et al. (+6) K. B. Mirzaev, V. A. Otdelenov, V. M. Tsvetov, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev
72	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Current and future use of vitamin D₃ in patients with COVID-19	I. N. Sychev, A. V. Matveev, D. A. Sychev
73	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Current and future use of dipyridamole in patients with COVID-19	I. S. Burashnikova, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
74	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Dexamethasone use in patients with COVID-19	V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
75	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Current and future use of remdesivir in patients with COVID-19	V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
76	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Current and future use of favipiravir in patients with COVID-19	A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev
77	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Use of unlicensed drugs and off-label drug use: focus on COVID-19	S. A. Mishinova, A. A. Zhuravkov, V. K. Zhuravko
78	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge	A. V. Krykov, V. A. Otdelenov, D. A. Sychev
79	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis	V. M. Tsvetov, I. N. Sychev, D. A. Sychev
80	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy	V. M. Tsvetov, Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev
81	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm»	V. A. Otdelenov, V. M. Tsvetov, D. A. Sychev
82	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Rationale for use mefloquine for COVID-19 treatment	V. A. Otdelenov, K. B. Mirzaev, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev
83	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention	K. B. Mirzaev, D. A. Sychev
84	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab	K. B. Mirzaev, Yu. Yu. Kiselev, D. A. Sychev
85	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Is it possible to use riamilovir to prevent infection and treat COVID-19?	V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev
86	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?	Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev
87	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Could canakinumab be used for COVID-19?	V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev
88	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Possibility for the use of bromhexine to prevent infection with SARS-CoV-2	K. A. Zagorodnikova, K. B. Mirzaev, D. A. Sychev
89	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Okt―28	Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel	V. A. Otdelenov, A. V. Krykov, D. A. Sychev
90	[GO]	Antibiotics and Chemotherapy	2020―Jun―08	Antiviral Activity of Kagocel^® in vitro Against Virus SARS-CoV-2	S. Ya. Loginova, V. N. Shchukina, S. V. Savenko, S. V. Borisevich
91	[GO]	Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice	2020―Mai―30	Socio-economic burden of COVID-19 in the Russian Federation	A. S. Kolbin, D. Yu. Belousov, Yu. M. Gomon, Yu. E. Balykina, I. G. Ivanov
92	[GO]	Antibiotics and Chemotherapy	2020―Mai―25	Studying the Effectiveness of Ribavirin® in the Experimental Form of Severe Acute Respiratory Syndrome	S. Ya. Loginova, V. N. Shchukina, S. V. Borisevich, R. A. Hamitov, V. A. Maksimov